Protean eGov Technologies Limited
NSE: PROTEANIT Enabled Services
Share price
₹640.65
+0.31% close of 9 Oct 2026
Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 8 Oct 2026, the close above is 9 Oct 2026.
Business score
How strong the business is, in one number. The parts behind it are in Pro.
61
out of 100 · worked out 9 Oct 2026
Your ratios
The numbers you want to see first. Tap Edit to change them.
Market cap
₹2,627 Cr
P/E ratio
30.5
P/B ratio
2.4
ROCE
12.7%
ROE
10.0%
Dividend yield
1.6%
Price & valuation chart
How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.
Answers
Simple answers to the questions investors ask most, from the company's own numbers.
How fast it has been growing
Sales grew 21.4% over the past year, and 6.3% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales slipped from 16.3% to 10.7% over the last three years.
Whether it grew faster than its sector
It grew 6.3% a year against a sector median of 14.5% — 8.2 percentage points slower.
Room to re-rate, or risk of de-rating
Too little price history yet to compare it with its own past.
Whether growth justifies the valuation
Its earnings are falling, so growth cannot justify the price.
| Profit growth | Price per ₹1 profit | Per 1% growth | |
|---|---|---|---|
| Protean eGov Technologies Limited — this one | -1%/yr | 30.5× | — |
| L&T Technology Services Limited | 6%/yr | 25.5× | ₹4.3 |
| Inventurus Knowledge Solutions Limited | 30%/yr | 38.2× | ₹1.3 |
| Tata Technologies Limited | -1%/yr | 44.5× | — |
| Netweb Technologies India Limited | 64%/yr | 99.9× | ₹1.6 |
| SAGILITY LIMITED | 86%/yr | 20.0× | ₹0.23 |
Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
How it compares with its peers
Against companies the exchange files under the same label (IT Enabled Services), it ranks 30 of 58 on returns, 38 of 54 on growth, 26 of 58 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
What makes it hard to beat — and is that still true?
No durable advantage shows in the numbers: it earns 12.7% on capital, ahead of 48% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
Whether its growth pays for itself
Yes — Over the last five years it made ₹332 crore of cash from the business, spent ₹161 crore on plant and equipment, and returned ₹145 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 8 years, about 71 arrived as cash. Its cash comes back faster than it used to: it went from being waiting 41 days for its cash to paid 8 days before it paid its own suppliers.
Profit reality check
Is the profit real cash? Simple checks on the accounts. Facts only, not advice.
8 of 10 checks clear · 80%
Latest result · Q1 FY27
What the last results showed. Whether management kept its word is in Pro.
Profit fell 75% on ₹18 crore of upfront project spending, with revenue up 19%
Announced 4 Aug 2026 · Consolidated · Unaudited
Revenue
₹251 Cr
Revenue vs last year
+19.0%
Revenue vs last quarter
-18.4%
Net profit
₹6 Cr
Profit vs last year
-75.4%
Profit vs last quarter
-80.7%
Net margin
2.3%
EPS
₹1.44
Earnings call transcript · 4 Aug 2026
Checklist before you investPRO
Points for and against, in one list.
Key numbers & peers
The main numbers grouped by topic, and how the company compares with similar ones.
Price
- Market cap
- ₹2,627 Cr
- Prev close
- ₹640.65
- 52w High
- ₹885
- 52w Low
- ₹444
- Enterprise value
- ₹2,388 Cr
- Beta
- 1.3
- Price CAGR 1y
- -23.0%
- Price CAGR 3y
- —
- Price CAGR 5y
- —
- Price CAGR 10y
- —
Ratios
- Return on assets
- 6.9%
- PEG ratio
- -30.3
- P/E ratio
- 30.5
- P/B ratio
- 2.4
- EV / EBITDA
- 21.4
- Industry P/E
- 26.9
- ROCE
- 12.7%
- ROCE 5y average
- 15.0%
- ROE
- 10.0%
- Debt / Equity
- 0.1
- Interest coverage
- 19.6
- Dividend yield
- 1.6%
- ROE 3y average
- 10.0%
- ROE last year
- 10.0%
Annual P&L
- Annual revenue
- ₹998 Cr
- Annual profit
- ₹101 Cr
- Operating margin
- 12.0%
- Net profit margin
- 10.1%
- EBITDA margin
- 11.6%
- Sales growth 3y
- 10.4%
- Sales growth 5y
- 10.6%
- Profit growth 3y
- -1.0%
- Profit growth 5y
- 3.0%
- EPS
- ₹24.8
- Sales growth TTM
- 21.0%
- Profit growth TTM
- -10.0%
- Dividend payout
- 40.0%
Quarter P&L
- Sales latest quarter
- ₹251 Cr
- Profit latest quarter
- ₹6 Cr
- YoY quarterly sales growth
- 19.0%
- YoY quarterly profit growth
- -75.4%
- OPM latest quarter
- 5.0%
Balance Sheet
- Book Value
- ₹263
- Face Value
- ₹10.0
- Total debt
- ₹87 Cr
- Total cash
- ₹187 Cr
- Borrowings
- ₹87 Cr
- Reserves / Equity
- 25.3
Cash Flow
- Operating cash flow
- ₹78 Cr
- Free cash flow
- ₹12 Cr
- FCF yield
- 0.2%
- Net cash flow
- ₹10 Cr
Shareholding
- Promoter holding
- —
- FII holding
- 6.0%
- DII holding
- 21.2%
- Public holding
- 72.8%
Peer comparison
| Company | Price ₹ | P/E | Mkt cap ₹ Cr | Div yield % | Profit qtr ₹ Cr | Profit var % | Sales qtr ₹ Cr | Sales var % | ROCE % |
|---|---|---|---|---|---|---|---|---|---|
| L&T Technology | 3,217.45 | 25.4 | 34,133 | 1.79 | 357.1 | 17.4 | 2,940.1 | 11.5 | 26.7 |
| Inventurus Knowl | 1,767.45 | 39.7 | 30,341 | 0.00 | 193.7 | 27.9 | 893.6 | 20.7 | 31.5 |
| Tata Technolog. | 703.70 | 43.9 | 28,574 | 1.19 | 180.8 | 6.2 | 1,664.6 | 33.8 | 20.9 |
| Netweb Technol. | 4,708.85 | 107.4 | 27,993 | 0.06 | 85.3 | 179.9 | 819.7 | 172.1 | 37.5 |
| Sagility | 43.47 | 19.7 | 20,350 | 0.35 | 216.8 | 53.0 | 1,963.5 | 27.6 | 13.4 |
| Affle 3i | 1,414.00 | 41.7 | 19,925 | 0.00 | 128.4 | 21.7 | 747.2 | 20.4 | 16.8 |
| ESDS Software | 1,424.55 | 135.3 | 16,697 | 0.00 | 29.3 | 14.0 | 133.7 | 7.3 | 30.2 |
| Protean eGov | 641.85 | 30.4 | 2,617 | 1.56 | 5.9 | -75.4 | 251.0 | 19.0 | 12.7 |
| Median | 226.40 | 26.9 | 858 | 0.00 | 8.8 | 20.8 | 110.9 | 20.7 | 16.4 |
Competes with: Affle 3i Limited, Amagi Media Labs Limited, Black Box Limited, Cyient Limited, ESDS Software Solution Limited, Inventurus Knowledge Solutions Limited, L&T Technology Services Limited, Netweb Technologies India Limited, SAGILITY LIMITED, Srit India Limited, Tata Technologies Limited
Quarterly results
Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.
| Line item | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 220 | 236 | 204 | 222 | 197 | 220 | 202 | 222 | 211 | 251 | 229 | 308 | 251 |
| Expenses | 186 | 199 | 207 | 200 | 181 | 188 | 187 | 204 | 194 | 221 | 197 | 270 | 239 |
| Material Cost | 0 | 0 | 0 | 0 | 0 | 0 | |||||||
| Change in Inventories | 0 | 0 | 0 | 0 | 0 | 0 | |||||||
| Purchases of Stock-in-Trade | 0 | 0 | 0 | 0 | 0 | 0 | |||||||
| Employee Cost | 50 | 58 | 60 | 56 | 58 | 69 | |||||||
| Other Expenses | 154 | 136 | 161 | 141 | 211 | 169 | |||||||
| Operating Profit | 34 | 36 | -3.08 | 22 | 15 | 32 | 16 | 18 | 16 | 29 | 32 | 38 | 12 |
| OPM % | 15 | 15 | -1.51 | 9.87 | 7.69 | 14 | 7.80 | 8.05 | 7.78 | 12 | 14 | 12 | 4.95 |
| Other Income | 13 | 13 | 29 | 13 | 19 | 14 | 19 | 17 | 29 | 15 | 10 | 15 | 15 |
| Exceptional items (within Other Income) | 0 | 0 | 0 | -3.95 | -0.75 | 0 | |||||||
| Interest | 0.22 | 0.41 | 0.52 | 0.52 | 0.50 | 0.49 | 0.26 | 1.09 | 1.52 | 1.51 | 1.57 | 2.08 | 2.65 |
| Depreciation | 4.91 | 5.48 | 6.19 | 11 | 6.77 | 7.14 | 5.81 | 8.10 | 11 | 10 | 11 | 14 | 18 |
| Profit before tax | 42 | 43 | 19 | 24 | 27 | 38 | 29 | 25 | 32 | 32 | 29 | 36 | 7.64 |
| Tax % | 23 | 24 | 21 | 18 | 22 | 25 | 20 | 19 | 26 | 26 | 24 | 17 | 23 |
| Net Profit | 32 | 33 | 15 | 19 | 21 | 28 | 23 | 20 | 24 | 24 | 23 | 30 | 5.86 |
| EPS in Rs | 7.96 | 8.10 | 3.77 | 4.77 | 5.21 | 6.92 | 5.66 | 5.03 | 5.88 | 5.88 | 5.54 | 7.48 | 1.44 |
| Diluted EPS in Rs | 5 | 5.85 | 5.85 | 5.52 | 7.46 | 1.43 |
Profit & loss
Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.
| Line item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 755 | 716 | 603 | 691 | 741 | 882 | 841 | 998 | 1,038 |
| Expenses | 578 | 568 | 518 | 567 | 623 | 792 | 760 | 882 | 926 |
| Material Cost | 0 | 0 | |||||||
| Change in Inventories | 0 | 0 | |||||||
| Purchases of Stock-in-Trade | 0 | 0 | |||||||
| Employee Cost | 189 | 233 | |||||||
| Other Expenses | 572 | 650 | |||||||
| Operating Profit | 177 | 148 | 85 | 124 | 118 | 89 | 80 | 116 | 112 |
| OPM % | 23 | 21 | 14 | 18 | 16 | 10 | 10 | 12 | 11 |
| Other Income | 33 | 38 | 49 | 79 | 42 | 68 | 68 | 68 | 55 |
| Exceptional items (within Other Income) | 0 | -4.70 | |||||||
| Interest | 2 | 2 | 1 | 0 | 1 | 2 | 2.34 | 6.68 | 8 |
| Depreciation | 28 | 27 | 17 | 17 | 18 | 27 | 28 | 47 | 53 |
| Profit before tax | 180 | 157 | 116 | 186 | 140 | 128 | 118 | 130 | 106 |
| Tax % | 32 | 23 | 20 | 22 | 24 | 24 | 22 | 23 | |
| Net Profit | 124 | 121 | 92 | 144 | 107 | 97 | 92 | 101 | 83 |
| EPS in Rs | 31 | 30 | 23 | 36 | 26 | 24 | 23 | 25 | 20 |
| Diluted EPS in Rs | 23 | 25 | |||||||
| Dividend Payout % | 0 | 0 | 0 | 126 | 38 | 42 | 44 | 40 |
Compounded growth
Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.
Compounded sales growth
- 10 years
- —
- 5 years
- 11%
- 3 years
- 10%
- TTM
- 21%
Compounded profit growth
- 10 years
- —
- 5 years
- 3%
- 3 years
- -1%
- TTM
- -10%
Stock price CAGR
- 10 years
- —
- 5 years
- —
- 3 years
- —
- 1 year
- -23%
Return on equity
- 10 years
- —
- 5 years
- 12%
- 3 years
- 10%
- Last year
- 10%
Balance sheet
What the company owns and what it owes, at the end of each year. ₹ crore.
| Line item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 40 | 40 | 40 | 40 | 40 | 40 | 41 | 41 |
| Reserves | 626 | 714 | 628 | 748 | 817 | 886 | 958 | 1,037 |
| Borrowings | 20 | 14 | 6 | 12 | 8 | 21 | 69 | 87 |
| Other Liabilities | 184 | 172 | 189 | 188 | 239 | 238 | 239 | 309 |
| Minority Interest | 0 | 0 | ||||||
| Total Liabilities | 870 | 940 | 863 | 988 | 1,104 | 1,185 | 1,307 | 1,474 |
| Fixed Assets | 157 | 64 | 57 | 65 | 63 | 86 | 153 | 167 |
| CWIP | 5 | 5 | 1 | 4 | 11 | 13 | 11 | 19 |
| Investments | 373 | 406 | 285 | 364 | 529 | 550 | 661 | 638 |
| Other Assets | 335 | 465 | 519 | 555 | 501 | 536 | 482 | 650 |
| Total Assets | 870 | 940 | 863 | 988 | 1,104 | 1,185 | 1,307 | 1,474 |
Cash flows
Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.
| Line item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 136 | 54 | 100 | 11 | -8 | 58 | 193 | 78 |
| Cash from Investing Activity | -104 | -13 | 116 | -139 | 12 | 19 | -159 | -14 |
| Cash from Financing Activity | -39 | -39 | -183 | -1 | -1 | -47 | -42 | -54 |
| Net Cash Flow | -7 | 2 | 32 | -129 | 2 | 29 | -8 | 10 |
| Free Cash Flow | 109 | 42 | 91 | 4 | -16 | 26 | 145 | 11 |
Ratios
How fast customers pay, how long stock sits, and how well capital earns — year by year.
| Line item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 88 | 107 | 120 | 106 | 103 | 78 | 63 | 75 |
| Cash Conversion Cycle | 88 | 107 | 120 | 106 | 103 | 78 | 63 | 75 |
| Working Capital Days | 25 | 99 | 100 | 41 | 18 | 20 | -24 | -8 |
| ROCE % | 22 | 15 | 19 | 17 | 14 | 12 | 13 |
Price trend
The price as a Renko brick chart: small moves drop out so the bigger path stands out.
Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.
Open interestPRO
Where option traders are positioned on this stock.
Industry numbers
The numbers that matter most in this industry, from the company's own filings.
1 when an audit qualification is filed as repetitive
0.00flag
2026-03-31
the company's own unlisted debt securities in default at period end
0.00cr
2026-06-30
the company's own loans / revolving facilities in default at period end (standalone filing)
0.00cr
2026-06-30
net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash
-239inr_cr
2026-03-31
guarantees / comfort given for promoter, promoter group, directors and KMP
0.00cr
2026-03-31
loans outstanding to promoter, promoter group, directors and KMP (governance filing)
0.00cr
2026-03-31
security given for the borrowing of promoter, promoter group, directors and KMP
0.00cr
2026-03-31
FY revenue / permanent employees + workers, same basis (calc)
1,18,95,113inr
2026-03-31
News
News and filings about Protean eGov Technologies Limited. Open one to see why it matters.
23 Sept, 21:20 IST · Company event · low impact
Significant movement in price has been observed in Protean eGov Technologies Limited.
18 Aug, 18:05 IST · Company event · medium impact
Protean eGov Technologies Limited has won a new order or contract
Supply chain
Who it buys from, sells to and competes with — as recorded in our map of company links.
Competes with
Products sold by
Sells to
- Bima Sugam India Federation · end-to-end development, implementation and maintenance of the Bima Sugam digital insurance…
- Government of Ethiopia · digital public infrastructure / national ID and AI-powered agriculture platform (export or…
- Government of India · Central AgriStack digital public infrastructure and data-exchange framework
- Income Tax Department, Government of India · Tax Information Network management; PAN/TAN issuance & reissuance; online PAN verification…
- Pension Fund Regulatory and Development Authority (PFRDA) · Central Recordkeeping Agency for NPS and APY (~97% NPS, 100% APY market share)
About
What the company is, from our own records: where it sits, where it makes things, and what it is made of.
- Sector
- Information Technology
- Industry
- IT Enabled Services
- Classification
- Information Technology › IT Enabled Services
- ISIN
- INE004A01022
News impact
Big market events that reach Protean eGov Technologies Limited, and how the effect spreads.
28 Jun, 13:20 IST · Market event · medium impact
As GST turns 10, focus shifts to AI-led compliance, faster refunds, simpler tax processes
Who it hits first
- Primary beneficiaries are UNLISTED GST-tech vendors (GSTN, Cleartax, Zoho, Tally) — no tradeable signal.
Who may gain
- Tax-tech/compliance SaaS and e-governance IT vendors winning incremental government digitisation mandates
- Refund-heavy SMEs/exporters via faster GST refund cycles (working-capital easing)
Along the supply chain
Downstream
Faster GST refunds and cleaner AI-based invoice/e-way-bill matching ease working-capital cycles and reduce shipment/credit disputes for refund-heavy SMEs and exporters downstream (textiles, pharma, auto-ancillaries, logistics) — a small operational tailwind.
Upstream
GST-tech delivery relies on cloud/data-centre capacity and systems integrators; an AI-compliance push modestly lifts upstream demand for cloud infrastructure and SI capacity serving GSTN and tax-tech vendors.
Where demand moves
Business
Incremental government digitisation demand flows to e-governance/tax-tech vendors — listed PROTEAN, ZAGGLE, NEWGEN, with most capture by unlisted incumbents (GSTN, Cleartax, Zoho, Tally); automation may partly substitute manual paid-compliance work, making the net demand for paid-compliance SaaS two-sided.
Capital
Theme is too diffuse and medium-term to drive meaningful capital rotation; any thematic interest would tilt toward listed tax-tech/e-gov pure-plays, but low magnitude keeps institutional flows muted.
How it spreads across sectors
BFSI
Faster GST refunds and AI-verified invoice data modestly ease SME working-capital cycles and can improve SME-lending underwriting visibility.
Information Technology
Incremental, medium-term govt digitisation demand for compliance automation; low magnitude, spread across listed and unlisted vendors.
codex additions
- Exporters/Textiles: faster refunds free blocked input-tax-credit, easing working capital (KPRMILL, TRIDENT, WELSPUNLIV)
- Pharma exporters: quicker refunds on inverted-duty/exports aid cash conversion (SUNPHARMA, AUROPHARMA, DIVISLAB)
- Auto ancillaries: simpler input-credit reconciliation across multi-state vendor chains (MOTHERSON, BOSCHLTD, UNOMINDA)
- Logistics: cleaner e-way-bill/invoice matching reduces shipment holds (DELHIVERY, TCI, VRLLOG)
- SME-focused NBFCs/supply-chain finance: GST-data-driven underwriting and invoice-backed lending (CREDITACC, SBFC, MASFIN)
- Staffing/BPO: transition work around GST process redesign near-term, automation headwind long-term (TEAMLEASE, SIS, QUESS)
When it plays out
Immediate
Minimal price reaction — anniversary/roadmap commentary, not a discrete policy action; no effective date or rate change.
Medium term
If AI-led compliance and faster refunds are funded, structural tailwind for listed e-gov/tax-tech vendors and a working-capital easing for refund-heavy SMEs/exporters; automation may compress manual paid-compliance demand.
Short term
Watch GST Council / GSTN announcements for concrete AI-compliance tenders or refund-cycle SLAs that would convert the theme into orders.
Other sectors it reaches
- {"causal_chain":"Faster GST refund processing lowers blocked input-tax-credit balances for exporters, improving working-capital turnover in refund-heavy textiles/apparel.","direction":"positive","example_tickers":["KPRMILL","TRIDENT","WELSPUNLIV"],"magnitude":"medium","notes":"Depends on actual refund-cycle compression and export order environment.","sector":"Exporters / Textiles \u0026 Apparel","time_horizon":"1_to_6_months"}
- {"causal_chain":"AI-led compliance and faster refunds reduce GST credit mismatches and speed cash recovery on exports/inverted-duty structures.","direction":"positive","example_tickers":["SUNPHARMA","AUROPHARMA","DIVISLAB"],"magnitude":"small","notes":"Large balance sheets dilute impact.","sector":"Pharmaceuticals \u0026 Healthcare Exporters","time_horizon":"1_to_6_months"}
- {"causal_chain":"Simpler GST processes lower compliance friction across multi-state supplier networks, easing input-credit reconciliation for component makers.","direction":"positive","example_tickers":["MOTHERSON","BOSCHLTD","UNOMINDA"],"magnitude":"small","notes":"More relevant for supplier-heavy businesses than OEMs.","sector":"Auto Ancillaries","time_horizon":"1_to_6_months"}
- {"causal_chain":"GST simplification plus AI compliance yields cleaner e-way-bill/invoice matching, fewer disputes and shipment holds.","direction":"positive","example_tickers":["DELHIVERY","TCI","VRLLOG"],"magnitude":"small","notes":"Incremental efficiency ripple on an already GST-benefited sector.","sector":"Logistics \u0026 Express Distribution","time_horizon":"1_to_4_weeks"}
- {"causal_chain":"Faster refunds and simplified input-credit reconciliation lower working-capital drag in high-inventory multi-state distribution.","direction":"positive","example_tickers":["DIXON","VOLTAS","BLUESTARCO"],"magnitude":"small","notes":"Strongest where input-credit accumulation is material.","sector":"Consumer Durables \u0026 Electronics Manufacturing","time_horizon":"1_to_6_months"}
- {"causal_chain":"Simpler GST and quicker refunds reduce compliance burden for project-based manufacturers with large vendor bases.","direction":"positive","example_tickers":["ABB","SIEMENS","BHEL"],"magnitude":"small","notes":"Operational rather than demand-transforming.","sector":"Capital Goods / Industrial Manufacturing","time_horizon":"1_to_6_months"}
- {"causal_chain":"Faster GST refunds and AI-driven invoice compliance improve verified SME cash-flow data, aiding underwriting and repayment visibility.","direction":"positive","example_tickers":["CREDITACC","SBFC","MASFIN"],"magnitude":"medium","notes":"GST-data-driven SME credit and invoice-backed lending.","sector":"SME-Focused NBFCs \u0026 Supply-Chain Finance","time_horizon":"1_to_6_months"}
- {"causal_chain":"GST simplification raises formalization among small manufacturers, lifting documented invoicing and compliant packaging demand.","direction":"positive","example_tickers":["TCPLPACK","UFLEX","JKPAPER"],"magnitude":"small","notes":"Second-order formalization effect; gradual.","sector":"Paper, Packaging \u0026 Printing","time_horizon":"1_to_6_months"}
- {"causal_chain":"AI-led compliance rollout still needs process redesign, reconciliations and audit support near-term, but automation reduces manual compliance headcount over time.","direction":"mixed","example_tickers":["TEAMLEASE","SIS","QUESS"],"magnitude":"small","notes":"Near-term transition work vs long-term automation headwind.","sector":"Staffing, BPO \u0026 Professional Services","time_horizon":"1_to_4_weeks"}
27 Jun, 18:25 IST · Market event · medium impact
Aarogya Setu 2.0 to drug registry: Govt to launch various digital healthcare initiatives on June 29
Who it hits first
- Health-IT / digital-health software vendors and system integrators that build the registries, citizen apps and interoperability layers (TATAELXSI, NETWEB, PROTEAN) see anticipatory demand
- National drug registry adds batch-level traceability/serialization compliance obligations for pharma makers (e.g. THEMISMED)
Who may gain
- TATAELXSI - healthcare digital-engineering vertical
- NETWEB - HPC / data-centre / AI-server backbone for registries and analytics
- PROTEAN - builder/operator of govt digital public infrastructure (closest fit to the health stack)
Along the supply chain
Downstream
Downstream, hospitals and diagnostics chains (HCG) must integrate interoperable records (near-term integration cost, gradual efficiency benefit) and pharma manufacturers/distributors (THEMISMED) must adapt dispensing, serialization and recall workflows to the national drug registry.
Upstream
Registry/app build-out pulls demand to upstream compute and connectivity suppliers - HPC servers and data-centre hardware (NETWEB) and last-mile/rural connectivity (NELCO) - plus cybersecurity and cloud-hosting vendors that secure sensitive health data.
Where demand moves
Business
Govt digital-health platform build-out creates new orders for health-IT software vendors, system integrators and digital-public-infrastructure operators (TATAELXSI, PROTEAN), and for the compute/data-centre backbone (NETWEB); pharma makers face new drug-registry compliance/serialization spend that flows to packaging, track-and-trace and pharma-IT vendors.
Capital
Anticipatory, theme-driven buying rotates toward listed health-IT and digital-public-infrastructure proxies (TATAELXSI, NETWEB, PROTEAN) on the launch news; given rich valuations and no awarded tenders, flows are likely shallow and selective rather than a broad sector re-rating.
How it spreads across sectors
Healthcare
Hospitals and diagnostics adopt interoperable records; near-term integration cost, gradual efficiency benefit (mixed)
Information Technology
Demand for govt health-IT build-out, system integration and digital-public-infrastructure platforms (positive, anticipatory)
Pharma
Drug registry drives serialization/traceability compliance spend; near-term cost, medium-term formalization (mixed)
codex additions
When it plays out
Immediate
June 29 launch generates theme-driven, anticipatory interest in listed health-IT / digital-public-infrastructure proxies; little fundamental change until tenders/contracts are awarded
Medium term
If the digital-health stack scales (registries, interoperability, AI workloads), structural demand builds for health-IT, data-centre/compute, cybersecurity and track-and-trace vendors; formalization may modestly favour organized pharma
Short term
Watch for actual procurement, tenders and system-integrator awards (incl. govt cloud/NIC routing) that would convert the theme into revenue; pharma begins assessing drug-registry compliance load
Other sectors it reaches
- {"causal_chain":"Interoperable health records and registries can reduce claims friction, improve underwriting data, enable faster pre-authorisation and fraud checks; insurers may need integration spend but benefit from cleaner digital rails over time.","direction":"mixed","example_tickers":["STARHEALTH","ICICIGI","NIACL"],"magnitude":"medium","notes":"Near-term compliance/integration cost; medium-term operating efficiency and product-design upside.","sector":"Health Insurance / Insurtech","time_horizon":"1_to_6_months"}
- {"causal_chain":"Citizen apps, telemedicine, provider registries and rural digital-health access increase dependence on reliable mobile data, broadband, enterprise connectivity and last-mile uptime.","direction":"positive","example_tickers":["BHARTIARTL","TATACOMM","INDUSTOWER"],"magnitude":"medium","notes":"Most visible where public-health workflows extend into rural clinics, pharmacies and district hospitals.","sector":"Telecom Connectivity / Broadband Infrastructure","time_horizon":"1_to_4_weeks"}
- {"causal_chain":"National registries, health IDs, consent systems, analytics and AI workloads require secure hosting, storage, uptime, cooling and backup-power infrastructure.","direction":"positive","example_tickers":["ANANTRAJ","BLUESTARCO","CUMMINSIND"],"magnitude":"medium","notes":"Indirect capex beneficiary; demand may route through cloud/data-centre operators and government system integrators.","sector":"Data Centres, Power Backup and Cooling","time_horizon":"1_to_6_months"}
- {"causal_chain":"Large-scale health records and drug registries raise privacy, identity, consent-management and cyber-risk requirements, creating demand for endpoint security, audits, encryption and incident-response services.","direction":"positive","example_tickers":["QUICKHEAL","TAC","63MOONS"],"magnitude":"medium","notes":"Health data sensitivity makes security spend politically and operationally hard to defer.","sector":"Cybersecurity / Digital Trust","time_horizon":"immediate"}
- {"causal_chain":"A national drug registry can push manufacturers and distributors toward better batch-level traceability, QR/barcode labelling, anti-counterfeit packaging and serialization workflows.","direction":"positive","example_tickers":["UFLEX","EPL","TCPLPACK"],"magnitude":"medium","notes":"Upside depends on how mandatory and granular registry compliance becomes.","sector":"Packaging, Labelling and Track-and-Trace","time_horizon":"1_to_6_months"}
- {"causal_chain":"Drug registry integration can change inventory verification, recall management, substitution checks and dispensing workflows for wholesalers, chains and online pharmacies.","direction":"mixed","example_tickers":["MEDPLUS","APOLLOHOSP","ENTERO"],"magnitude":"medium","notes":"Compliance burden initially negative; larger organised players may gain share from better ability to integrate.","sector":"Pharma Distribution / Retail Pharmacy","time_horizon":"1_to_4_weeks"}
- {"causal_chain":"Better drug traceability and digital inventory records can increase formal logistics requirements, especially for temperature-sensitive medicines, vaccines and recall-ready supply chains.","direction":"positive","example_tickers":["TCIEXP","MAHLOG","VRLLOG"],"magnitude":"small","notes":"More relevant if registry rules extend into distribution-chain reporting and batch-level movement tracking.","sector":"Logistics and Cold Chain","time_horizon":"1_to_6_months"}
- {"causal_chain":"Provider-focused digital solutions and interoperable records increase demand for connected devices, hospital IT-linked equipment, patient monitoring systems and digitised clinical workflows.","direction":"positive","example_tickers":["POLYMED","BPL","KRSNAA"],"magnitude":"small","notes":"Indirect beneficiary through hospitals upgrading devices and workflow capture around digital records.","sector":"Medical Devices and Hospital Equipment","time_horizon":"1_to_6_months"}
- {"causal_chain":"Citizen health apps, digital claims, teleconsultations, pharmacy purchases and public-health benefit flows can increase embedded payment, reconciliation and identity-linked transaction use cases.","direction":"positive","example_tickers":["PAYTM","NSDL","CAMS"],"magnitude":"small","notes":"Likely second-order; strongest if government health apps include payments, reimbursements or benefit-transfer layers.","sector":"Digital Payments / Fintech Rails","time_horizon":"1_to_6_months"}
Dividends, splits & big trades
Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.
Dividends
| 28 Aug 2026 | unspecified | ₹10 |
|---|---|---|
| 29 Aug 2025 | unspecified | ₹10 |
Splits, bonuses & buybacks
- daily-prices repair: 3 rows from NSE's archive (replace 1, delete 1, insert 1), 2025-03-18..2026-02-01 (docs/flat_day_repair.md)1× · 18 Mar 2025
Bulk & block deals
| Date | Who | Bought / sold | Shares | Price |
|---|---|---|---|---|
| 28 Sep 2026 | HRTI PRIVATE LIMITED | SELL | 2,43,192 | ₹698.72 |
| 28 Sep 2026 | HRTI PRIVATE LIMITED | BUY | 2,42,723 | ₹696.70 |
| 25 Sep 2026 | HRTI PRIVATE LIMITED | BUY | 2,19,727 | ₹671.97 |
| 25 Sep 2026 | HRTI PRIVATE LIMITED | SELL | 2,19,167 | ₹669.04 |
| 22 Sep 2026 | MICROCURVES TRADING PRIVATE LIMITED | BUY | 7,72,945 | ₹630.66 |
| 22 Sep 2026 | MICROCURVES TRADING PRIVATE LIMITED | SELL | 7,72,889 | ₹631.00 |
| 22 Sep 2026 | ALPHAGREP SECURITIES PRIVATE LIMITED | BUY | 7,43,508 | ₹627.86 |
| 22 Sep 2026 | ALPHAGREP SECURITIES PRIVATE LIMITED | SELL | 7,43,508 | ₹627.47 |
| 22 Sep 2026 | QE SECURITIES LLP | SELL | 7,22,847 | ₹626.16 |
| 22 Sep 2026 | QE SECURITIES LLP | BUY | 7,20,296 | ₹626.61 |
Documents
Annual reports, results presentations and earnings calls, straight from the source.
- Annual report · 2025-2628 Aug 2026
- Earnings call · Q1FY274 Aug 2026
- Results presentation30 Jun 2026
- Earnings call21 May 2026
- Earnings call12 Feb 2026
- Annual report · 2024-2525 Aug 2025
Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.